García RME, Armas PBA, Koelig PR, Armas MK

Language: Spanish
References: 12
Page: 118-122
PDF size: 429.75 Kb.

ABSTRACT

Background: the universally accepted TNM cancer staging system (tumor, nodes, metastasis) was created with the purpose of offering quality assistance to patients with cancer, establishing prognoses, improving research, and assessing the disease entity in groups of ill patients.
Objective: to communicate the proposal of T descriptor´s classification in the eight edition of the TNM.
Methods: a search in Pubmed, Scielo, Redalycs databases was carried out using the following descriptors: staging, TNM, lung cancer.
Results: it was possible to determine that from one to five cms, each cm separates the tumors regarding patients’ prognosis and the size of the tumor.
Conclusions: lung cancer anatomical extension was described by TNM classification system. The latter makes the former remain as the most important prognosis factor, based on the tumor´s characteristics, diagnostic methods and treatment strategies. This system is subject to constant revision.

REFERENCES

1. Denoix PF. Enquete permanente Sanz les centres anti-cancereux. Bull Inst Nat Hyg (Paris). 1946;1:70-5.

2. Denoix PF. The TNM staging system. Bull Inst Nat Hyg (Paris). 1952;7:743.

3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:17-107.

4. International Union against Cancer. Lung tumours. In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumours. 5th Ed. New York: Wiley-Liss; 1997. p. 917.

5. Goldstraw P, Crowley JJ. The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol. 2006;1:281-6.

6. García Rodríguez ME. Estadificación y valoración mediastínica del cáncer del pulmón. Rev Cubana Cir [Internet]. Dic 2010 [citado 19 Jul 2015];49(4):[aprox. 11 p.]. Disponible en: http://scielo.sld.cu/scielo.php? script=sci_arttext&pid=S0034- 74932010000400012&lng=es

7. García Rodríguez ME, Armas Pérez BA, Armas Moredo K. Actualización en el tratamiento del cáncer pulmonar de células no pequeñas en etapa IIIA con afectación N2. Rev Cubana Cir [Internet]. Sep 2012 [citado 3 Jun 2013];51 (3):[aprox. 6 p.]. Disponible en: http:// scielo.sld.cu/scielo.php? script=sci_arttext&pid=S0034749320120003 00003&lng=es

8. Detterbeck FC, Boffa DJ, Tanoue LT, Wilson LD. Details and Difficulties regarding the New Lung Cancer Staging System. Chest. 2010;137:1172-1180.

9. Sánchez de Cos J, Hernández Hernández J, Jiménez López M, Padrones Sánchez S, Rosell Gratacós A, Ramón Rami Porta R. Normativa SEPAR sobre estadificación del cáncer de pulmón. Arch Bronconeumol. 2011;47:454-65.

10. Academia Nacional de Medicina Buenos Aires [Internet]. Argentina: Academia Nacional de Medicina; c2012-2016 [citado 3 Jun 2013]. Consenso Nacional Inter-Sociedades sobre Carcinoma de pulmón no células pequeñas (CPNCP); [aprox. 98 pantallas]. Disponible en: http://www.acamedbai.org.ar/ consensos/consensocadepulm

11. Rami-Porta R, Bolejack V, Ball D, Kim J, Lyons G, Rice T, et al. "The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10 (7):990-1003.

12. Fibla JJ, Cassivi SD, Decker PA, Allen MS, Darling GE, Landreneau RJ, et al. Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030). Eur J Cardiothorac Surg. 2013;43(5):911-4.